Chemotherapy News and Research

Latest Chemotherapy News and Research

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

New UC M program to test comprehensive care physician model

Patients who are frequently hospitalized account for a disproportionate amount of health care spending in the United States. Working with a $6.1 million grant, a new University of Chicago Medicine program will test whether an updated version of the traditional general practitioner can reduce spending while also improving care for these patients.

19 Jul 2012

UCSF Medical Center acquires BSD-2000 Hyperthermia System

BSD Medical Corporation announced today that the prestigious University of California San Francisco Medical Center (UCSF Medical Center) has purchased a BSD-2000 Hyperthermia System (BSD-2000).

19 Jul 2012

New roadmap provides expert guidance on how to reduce racial and ethnic health disparities

Major disparities exist along racial and ethnic lines in the United States for various medical conditions, but guidance is scarce about how to reduce these gaps. Now, a new "roadmap" has been unveiled to give organizations expert guidance on how to improve health equity in their own patient populations.

18 Jul 2012

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

18 Jul 2012

Combination of Dox with MCP shows promise against prostate cancer

Doxorubicin (Dox) is an effective anti-cancer drug, but it's also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients, however, researchers may have found an answer through combination therapy.

18 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

MSU nursing researcher’s Wii-Fit program helps lung cancer patients reduce fatigue

With the support of a $379,741 grant from the National Cancer Institute and the Nintendo Wii game system, nursing researcher Amy Hoffman aims to help lung cancer patients reduce fatigue and get more exercise as they transition from the hospital to the home after surgery.

17 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

New drug combination could offer hope to children with neuroblastoma

A new drug combination could offer hope to children with neuroblastoma - one of the deadliest forms of childhood cancer - by boosting the effectiveness of a promising new gene-targeted treatment.

12 Jul 2012

Study details how resistance to targeted drug therapy emerges in colorectal cancers

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

12 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Collaboration is key to effective cancer palliation

Collaborative decision-making and frequent meetings between palliative care teams and oncology staff are the most critical factors for improving end-of-life care, say French researchers.

11 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Chemotherapy improves survival for patients with periampullary cancer following resection

Patients who had surgery for periampullary cancer (a variety of types of cancer that are located in and near the head of the pancreas, including an area called the ampulla where the bile duct joins up with the pancreatic duct to empty their secretions into the upper small intestine) and received chemotherapy had a statistically significant survival benefit, compared to patients who did not receive chemotherapy, after adjusting for prognostic variables, according to a study in the July 11 issue of JAMA.

11 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results.

10 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

New UC M program to test comprehensive care physician model

UCSF Medical Center acquires BSD-2000 Hyperthermia System

New roadmap provides expert guidance on how to reduce racial and ethnic health disparities

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

Combination of Dox with MCP shows promise against prostate cancer

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

MSU nursing researcher’s Wii-Fit program helps lung cancer patients reduce fatigue

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

New drug combination could offer hope to children with neuroblastoma

Study details how resistance to targeted drug therapy emerges in colorectal cancers

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Collaboration is key to effective cancer palliation

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

Chemotherapy improves survival for patients with periampullary cancer following resection

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

DRCRF names 21 new Damon Runyon Fellows

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

ImmunoCellular receives Japanese patent allowance for brain cancer technology

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in